Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309781253> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4309781253 endingPage "140400" @default.
- W4309781253 startingPage "140400" @default.
- W4309781253 abstract "• Thiostrepton-loaded nanoliposomes (ThioLipos) was developed and evaluated. • ThioLipo inhibits cell proliferation and PD-L1 expression of colon tumor. • CD3+ T cells were increased by 3.8-folds in ThioLipo-treated tumors. • ThioLipo induces no toxic side effects on normal tissues. • ThioLipo can be used as promising nano-immunotherapeutics for cancer patients. Immune checkpoint inhibitors (ICIs) have emerged as effective cancer therapeutic agents. However, immune-related adverse effects, high treatment costs, and low therapeutic efficacy against rapidly growing tumors limit their clinical applications. Here, we developed thiostrepton-loaded nanoliposomes (ThioLipos) as novel therapeutic drugs to overcome the limitations of ICIs and for enhancing the efficacy of cancer immunotherapy. Thiostrepton, a forkhead box M1 inhibitor, induced a significant reduction in programmed death ligand-1 (PD-L1) levels and viability of human and murine colon cancer cells. The therapeutic potential of ThioLipos in cancer immunotherapy was evaluated using a MC38 syngeneic tumor model. For mice with rapidly growing colon tumors, ThioLipo treatment alone resulted in therapeutic outcomes similar to those of ICI treatment. Moreover, combined therapy with ThioLipos and ICIs (anti-4-1BB or anti-PD-1 antibodies) resulted in synergistic tumor growth inhibition when compared with ThioLipo or ICI treatment alone, and no side effects were observed in normal tissues. These results suggest that ThioLipos can be used as promising nano-immunotherapeutics for overcoming the limitations of ICIs and enhancing the efficacy of cancer immunotherapy." @default.
- W4309781253 created "2022-11-29" @default.
- W4309781253 creator A5000169747 @default.
- W4309781253 creator A5004711168 @default.
- W4309781253 creator A5019288901 @default.
- W4309781253 creator A5020465529 @default.
- W4309781253 creator A5026373258 @default.
- W4309781253 date "2023-02-01" @default.
- W4309781253 modified "2023-09-25" @default.
- W4309781253 title "FOXM1 inhibitor-loaded nanoliposomes for enhanced immunotherapy against cancer" @default.
- W4309781253 cites W1483080671 @default.
- W4309781253 cites W1967235705 @default.
- W4309781253 cites W1991603403 @default.
- W4309781253 cites W1994401890 @default.
- W4309781253 cites W2039123767 @default.
- W4309781253 cites W2066002010 @default.
- W4309781253 cites W2074618914 @default.
- W4309781253 cites W2084659308 @default.
- W4309781253 cites W2136731993 @default.
- W4309781253 cites W2594017813 @default.
- W4309781253 cites W2884616676 @default.
- W4309781253 cites W2901619788 @default.
- W4309781253 cites W2911909558 @default.
- W4309781253 cites W2913411883 @default.
- W4309781253 cites W2914311090 @default.
- W4309781253 cites W2919428266 @default.
- W4309781253 cites W2921225184 @default.
- W4309781253 cites W2945590213 @default.
- W4309781253 cites W2991312126 @default.
- W4309781253 cites W3036452718 @default.
- W4309781253 cites W3084157711 @default.
- W4309781253 cites W3118768174 @default.
- W4309781253 cites W3131682687 @default.
- W4309781253 cites W4205315499 @default.
- W4309781253 cites W4292260712 @default.
- W4309781253 doi "https://doi.org/10.1016/j.cej.2022.140400" @default.
- W4309781253 hasPublicationYear "2023" @default.
- W4309781253 type Work @default.
- W4309781253 citedByCount "1" @default.
- W4309781253 countsByYear W43097812532023 @default.
- W4309781253 crossrefType "journal-article" @default.
- W4309781253 hasAuthorship W4309781253A5000169747 @default.
- W4309781253 hasAuthorship W4309781253A5004711168 @default.
- W4309781253 hasAuthorship W4309781253A5019288901 @default.
- W4309781253 hasAuthorship W4309781253A5020465529 @default.
- W4309781253 hasAuthorship W4309781253A5026373258 @default.
- W4309781253 hasConcept C121608353 @default.
- W4309781253 hasConcept C126322002 @default.
- W4309781253 hasConcept C170240278 @default.
- W4309781253 hasConcept C2777701055 @default.
- W4309781253 hasConcept C2780674031 @default.
- W4309781253 hasConcept C29537977 @default.
- W4309781253 hasConcept C502942594 @default.
- W4309781253 hasConcept C71924100 @default.
- W4309781253 hasConceptScore W4309781253C121608353 @default.
- W4309781253 hasConceptScore W4309781253C126322002 @default.
- W4309781253 hasConceptScore W4309781253C170240278 @default.
- W4309781253 hasConceptScore W4309781253C2777701055 @default.
- W4309781253 hasConceptScore W4309781253C2780674031 @default.
- W4309781253 hasConceptScore W4309781253C29537977 @default.
- W4309781253 hasConceptScore W4309781253C502942594 @default.
- W4309781253 hasConceptScore W4309781253C71924100 @default.
- W4309781253 hasFunder F4320321681 @default.
- W4309781253 hasFunder F4320322014 @default.
- W4309781253 hasFunder F4320322030 @default.
- W4309781253 hasFunder F4320322034 @default.
- W4309781253 hasFunder F4320322052 @default.
- W4309781253 hasLocation W43097812531 @default.
- W4309781253 hasOpenAccess W4309781253 @default.
- W4309781253 hasPrimaryLocation W43097812531 @default.
- W4309781253 hasRelatedWork W2030612376 @default.
- W4309781253 hasRelatedWork W2755360248 @default.
- W4309781253 hasRelatedWork W2893846263 @default.
- W4309781253 hasRelatedWork W2973160925 @default.
- W4309781253 hasRelatedWork W2996772275 @default.
- W4309781253 hasRelatedWork W3033719114 @default.
- W4309781253 hasRelatedWork W3195008613 @default.
- W4309781253 hasRelatedWork W4214943367 @default.
- W4309781253 hasRelatedWork W4292260712 @default.
- W4309781253 hasRelatedWork W4310278132 @default.
- W4309781253 hasVolume "454" @default.
- W4309781253 isParatext "false" @default.
- W4309781253 isRetracted "false" @default.
- W4309781253 workType "article" @default.